Major Ingredients

Budetrol 6/200 Mycap: Each Capsule Contains Formoterol Fumarate Dihydrate BP 6 mcg and Budesonide BP 200 mcg inhalation powder.

Major Functionality

Asthma : Formoterol and Budesonide combination is indicated in the regular treatment of asthma where use of a combination (inhaled corticosteroid and long acting β2-agonist) is appropriate. This includes : • Patients who are not adequately controlled with inhaled corticosteroid therapy and as needed inhaled short-acting β2-adrenoceptor agonists. • Patients who are already adequately controlled on regular separate long-acting β2-agonist and inhaled corticosteroid therapies. COPD : Formoterol and Budesonide combination is indicated in the regular treatment of adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) with frequent symptoms despite β2-agonist use and a history of exacerbations.

Manufacture Information

Drug International Limited was incorporated under the Registrar of Joint Stock Companies in 1974 as a Private Limited Company. The company commenced formulation and production in 1983 and emerged as a pioneer in Bangladesh for adding a state of the art oral solid dosage plant. Since inception, Drug International Limited's primary objective has been to meet guidelines provided by major global regulatory bodies such as the World Health Organization Good Manufacturing Practices (WHO cGMP) guidelines.